Funding sources No external funding.
Clinical and Laboratory Investigations
Applicability of dermoscopy for evaluation of patients' response to nonablative therapies for the treatment of superficial basal cell carcinoma
Article first published online: 15 APR 2014
© 2013 British Association of Dermatologists
British Journal of Dermatology
Volume 170, Issue 4, pages 809–815, April 2014
How to Cite
Apalla, Z., Lallas, A., Tzellos, T., Sidiropoulos, T., Lefaki, I., Trakatelli, M., Sotiriou, E., Lazaridou, E., Evangelou, G., Patsatsi, A., Kyrgidis, A., Stratigos, A., Zalaudek, I., Argenziano, G. and Ioannides, D. (2014), Applicability of dermoscopy for evaluation of patients' response to nonablative therapies for the treatment of superficial basal cell carcinoma. British Journal of Dermatology, 170: 809–815. doi: 10.1111/bjd.12749
Conflicts of interest None declared.
- Issue published online: 15 APR 2014
- Article first published online: 15 APR 2014
- Accepted manuscript online: 27 NOV 2013 07:16AM EST
- Manuscript Accepted: 18 NOV 2013
Applicability of dermoscopy in evaluation of outcome and monitoring of superficial basal cell carcinoma (sBCC) after nonablative therapies has not been sufficiently assessed.
Certain dermoscopic criteria, namely pigmented structures, ulceration and arborizing vessels, have been suggested to predict the presence of residual disease [residual disease-associated dermoscopic criteria (RDADC)]. We aimed to assess this hypothesis.
Patients and methods
Lesions exhibiting RDADC 3 months after treatment were biopsied and in the case of histopathological confirmation were excised. Lesions characterized by white/red structureless areas, superficial fine telangiectasias, or lacking any dermoscopic criterion, were monitored for 12 months.
At the 3-month evaluation, one or more of the RDADC were detected in 25/98 (25·5%) sBCCs, in which histology confirmed tumour persistence. In 45 (61·6%) of the 73 remaining lesions, dermoscopy showed white/red structureless areas and/or superficial fine telangiectasias. Twenty-eight lacked any dermoscopic criterion of sBCC. The two latter groups entered follow-up. In total, disease recurred in 13 (17·8%) of the 73 lesions.
RDADC accurately predict residual disease. Absence of dermoscopic criteria of sBCC safely predicts complete histopathological clearance. Detection of white/red structureless areas and/or superficial fine telangiectasias warrants close monitoring to recognize early recurrence.